TransMedics Reports Third Quarter 2024 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/26/2026
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Stock action shows confidence in central banks: BofA’s Hartnett
- Oil prices slide about 2% as US, Iran explore path out of war
- Why stocks held up despite rising yields and $100 oil? These 2 words explain it
- Barclays asks if equity markets are nearing the boiling point
- White House blocks CNN from Air Force One trip, Washington Post reports
- Merck and Daiichi Sankyo withdraw lung cancer drug application
- Exclusive-SK Hynix's Solidigm weighs IPO that could value the unit at up to $150 billion, sources say
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Fox Factory sells Marucci Sports for $225M, cuts debt
TransMedics Group (TMDX) PT Lowered to $125 at Oppenheimer
October 29, 2024 6:04 AM EDTOppenheimer analyst Suraj Kalia lowered the price target on TransMedics Group (NASDAQ: TMDX) to $125.00 (from $200.00) while maintaining a Outperform rating.
The analyst comments "TransMedics reported 3Q24 revs. of $108.8M, below our/consensus $117.1M/$115.0M estimates. In Q3, our calculated US transplant shares were 21%/27%/4%... More
TransMedics Group (TMDX) Misses Q3 EPS by 17c, Updates Guidance
October 28, 2024 4:11 PM EDTTransMedics Group (NASDAQ: TMDX) reported Q3 EPS of $0.12, $0.17 worse than the analyst estimate of $0.29. Revenue for the quarter came in at $108.8 million versus the consensus estimate of $114.99 million.
GUIDANCE:
TransMedics Group sees FY2024 revenue of $425-445 million, versus the consensus of... More
